TICKERNERD
Menu
FDMTFDMTHealthcare · Biotechnology

FDMT Stock Forecast: 4D Molecular Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$13
−2.37% on the day

The 12 Wall Street analysts covering 4D Molecular Therapeutics, Inc. hold a median 12-month price target of $31 — +131.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 10 Sept 2026 — in the upper half.

Market cap
$745.2M
Ticker Nerd rank
53 / 100
Median analyst target
$31
Analysts covering
12
Revenue$3.8M+25106.7% y/y
Operating income−$77.0M
Net income−$72.9M
Free cash flow−$70.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.4%
1M
+14.8%
YTD
+75.6%
1Y
+86.3%
From 52W high
−21.4%
From 52W low
+99.5%
$7
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FDMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 4D Molecular Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Accruals
68
Growth
60
Value
58
Size
48
Revisions
47
Volatility
46
Quality
44
Issuance
11

Momentum (94): The shares have been drifting up relative to others.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FDMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FDMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26FDMTHigh $37Median $31Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $18Median $31High $37

The green dot is the last close — the median target sits +131.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 July 2026B. Riley SecuritiesInitiatesBuy$37
31 July 2026B. Riley SecuritiesInitiatesBuy—
20 July 2026HC Wainwright & Co.ReiteratesBuy—
20 July 2026HC Wainwright & Co.ReiteratesBuy$36
30 Mar 2026JefferiesAssumesBuy$40 → $21
20 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026Chardan CapitalMaintainsBuy—
19 Mar 2026RBC CapitalMaintainsOutperform—
28 Jan 2026BarclaysInitiatesOverweight—
18 Dec 2025Chardan CapitalMaintainsBuy—
11 Nov 2025BarclaysMaintainsOverweight—
11 Nov 2025Chardan CapitalMaintainsBuy—
11 Nov 2025RBC CapitalMaintainsOutperform—
21 Oct 2025RBC CapitalReiteratesOutperform—
12 Aug 2025Chardan CapitalMaintainsBuy—
12 Aug 2025Roth CapitalMaintainsBuy—
1 Aug 2025Chardan CapitalMaintainsBuy—
3 July 2025Chardan CapitalMaintainsBuy—
9 May 2025BarclaysMaintainsOverweight—
9 May 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FDMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FDMT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, 4D Molecular Therapeutics, Inc. returned +86.3% against +17.5% for the S&P 500, dividends included.

FDMT vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26FDMTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FDMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

4D Molecular Therapeutics, Inc. (FDMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.6×

Cheaper than 90% of US stocks

Price / sales
8.1×

Cheaper than 16% of US stocks

Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
−2.2×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
25106.7%

Higher than 99% of US stocks

Earnings growth (YoY)
25106.7%

Higher than 99% of US stocks

Gross margin
—
Operating margin
−2037.2%

Higher than 4% of US stocks

Net margin
−194.7%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−43.3%

Higher than 23% of US stocks

Return on assets
−25.1%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

4D Molecular Therapeutics, Inc. (FDMT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • 4D Molecular Therapeutics, Inc. has a market value of $745.2M and an enterprise value of $423.1M.

  • Revenue in the twelve months to 30 June 2026: $92.0M. The latest quarter grew 25106.7% year on year.

  • Net income over the same four quarters: −$179.2M, a −194.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$156.0M.

  • Shares outstanding: 55.2M.

  • Trailing P/E: −5.6×; forward P/E: −3.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • 4D Molecular Therapeutics, Inc. employs 196 people — $469K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

FDMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FDMT4D Molecular Therapeutics, Inc.$745.2M
53
ACHVAchieve Life Sciences, Inc.$747.4M
29
GYREGyre Therapeutics, Inc.$751.4M
44
MNPRMonopar Therapeutics, Inc.$734.8M
54
MPLTMapLight Therapeutics, Inc.$728.5M
12
CTMXCytomX Therapeutics, Inc.$724.2M
47
AURAAura Biosciences, Inc.$722.7M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 4D Molecular Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FDMT news & analysis

4DMT Announces New Employment Inducement Grants

GlobeNewsWire · 11 Sept 2026neutral

On September 8, 2026, the compensation committee of 4D Molecular Therapeutics' board of directors granted 96,000 Restricted Stock Units to seven new non-executive employees under the company's 2025 Employment Inducement Award Plan, in accordance with Nasdaq Rule 5635(c)(4).

Why it matters — This new-hire equity grant indicates the company is attracting and onboarding employees, though it is a routine inducement arrangement rather than a substantive business development event.

4DMT to Participate in Upcoming Investor Conferences

GlobeNewsWire · 25 Aug 2026neutral

4D Molecular Therapeutics announced that its management will present and hold one-on-one meetings at upcoming investor conferences scheduled for September. The announcement was made on August 25, 2026.

Why it matters — Participation in investor conferences signals the company's ongoing outreach to the investment community and could increase visibility for FDMT among investors.

4DMT Announces New Employment Inducement Grants

GlobeNewsWire · 14 Aug 2026neutral

4D Molecular Therapeutics granted 35,200 Restricted Stock Units to five new non-executive employees on August 11, 2026, under the company's 2025 Employment Inducement Award Plan.

Why it matters — The inducement grants signal the company is hiring and incentivizing new talent, which may be of interest to shareholders tracking team growth.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 13 Aug 2026neutral

4D Molecular Therapeutics reported a Q2 loss of $1.04 per share, in line with the Zacks Consensus Estimate and compared to a loss of $0.98 per share a year ago. Revenue results topped analyst estimates.

Why it matters — FDMT watchers would track this quarterly earnings report to see how the company's financial results compare with analyst expectations and prior-year performance.

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewsWire · 13 Aug 2026positive

4D Molecular Therapeutics reported its Q2 2026 financial results and operational highlights, including completed enrollment in the 4D-150 4FRONT-2 wet AMD Phase 3 trial (topline data expected in H2 2027), topline 4FRONT-1 data expected in Q2 2027, positive two-year PRISM Phase 2b data, a planned DME Phase 3 initiation in Q3 2026, an Investor Day on October 21, 2026, a credit facility with Hercules Capital for up to $200 million, and $431 million in cash expected to fund operations into H2 2028.

Why it matters — The update outlines key near-term trial readouts and milestones plus a cash position expected to support operations through the second half of 2028, giving FDMT watchers a view of upcoming catalysts and financial runway.

FAQ

Frequently asked questions about FDMT stock

What is the FDMT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering 4D Molecular Therapeutics, Inc. have a median 12-month price target of $31, with estimates ranging from $18 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FDMT stock a buy right now?

Of the 12 analysts covering 4D Molecular Therapeutics, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 4D Molecular Therapeutics, Inc. 53 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FDMT?

As at 10 Sept 2026, 4D Molecular Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will FDMT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +131.6% from the last close, and Ticker Nerd's factor model ranks 4D Molecular Therapeutics, Inc. 53 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FDMT stock forecast for 2030?

No analyst covering 4D Molecular Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FDMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $37 over the next 12 months.

How has FDMT stock performed over the past year?

4D Molecular Therapeutics, Inc. returned +86.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 4D Molecular Therapeutics, Inc. do?

4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform.

What is the latest news on FDMT?

The most recent item we track (GlobeNewsWire, 11 Sept 2026): "4DMT Announces New Employment Inducement Grants". On September 8, 2026, the compensation committee of 4D Molecular Therapeutics' board of directors granted 96,000 Restricted Stock Units to seven new non-executive employees under the company's 2025 Employment Inducement Award Plan, in accordance with Nasdaq Rule 5635(c)(4).

Company

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform. The company designs customized adeno-associated virus, or AAV, vectors intended to deliver therapeutic payloads to specific tissues and disease areas with precision. Its current clinical development programs are concentrated in retina and pulmonology, reflecting a portfolio aimed at treating serious conditions through targeted gene delivery. In ophthalmology, the company is advancing therapies for retinal vascular diseases and other eye disorders, while its respiratory work includes programs for lung-directed treatment of genetic disease. 4D Molecular Therapeutics, Inc. plays a specialized role in the gene therapy market by combining vector engineering, tissue targeting, and disease-focused development to support next-generation genetic medicine candidates.

CEO Dr. David H. Kirn M.D. · 196 employees · United States · https://www.4dmoleculartherapeutics.com